Axoft, a neurotechnology company, announced it has raised an oversubscribed $55 million Series A led by C.P. Group Innovation. Alumni Ventures, the Stanford President's Venture Fund, Hillhouse Investment and Gaorong Ventures also participated in the round. With more than $60 million in total funding raised, Axoft will use the capital to expand its current clinical trials globally and progress U.S. regulatory approval of its implantable Brain-Computer Interfaces (iBCIs), which have already demonstrated the ability to safely decode brain signals, and offer a path for improving the standard of care for prognosis and communication in disorders of consciousness. Axoft will also use the capital to build a good manufacturing practice (GMP) facility to mass produce its iBCIs.